|Mr. David R. Epstein B.Sc., M.B.A.||Exec. Chairman||495k||N/A||1962|
|Dr. Pablo J. Cagnoni M.D., Ph.D.||CEO, Pres & Director||971.45k||N/A||1963|
|Mr. Jose I. Carmona||CFO, Principal Accounting Officer & Treasurer||659.2k||N/A||1972|
|Ms. Dannielle Appelhans||Chief Operating Officer||422.98k||N/A||1983|
|Mr. Laurence A. Turka M.D.||Chief Scientific Officer and Head of Research & Translational Medicine||626.55k||N/A||1958|
|Ms. Maiken Keson-Brookes||Chief Legal Officer & Corp. Sec.||607.74k||N/A||1973|
|Mr. Spencer Fisk||Sr. VP & Chief Technical Operations Officer||N/A||N/A||N/A|
|Mr. Mark J. Hernon||Chief Information Officer||N/A||N/A||1964|
|Ms. Lori Melancon||Chief Corp. Affairs Officer||N/A||N/A||N/A|
|Ms. Marissa Hanify||Director of Corp. Communications||N/A||N/A||N/A|
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Rubius Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 8; Compensation: 7.